2 May 2005
Boxmeer, May 2005 – For the second year Intervet International bv, the animal health business of Akzo Nobel, offer the Dieter Lütticken award to promote scientists or life science research institutions working in research areas that serve the 3R-concept i.e. reducing, refining or replacing the use of animals in testing for development and production of veterinary medicines. The total funding for the award is 20,000 Euro. Application deadline is 30/09/2005.
The international award, established in 2004 will be given to scientists or public institutions that have delivered excellent contributions to the 3Rs for the development and production of veterinary medicinal products, documented by a publication in the last two years. The award scope covers in vitro models used in R&D which replace animal testing for licensing purposes as well as studies avoiding the use of animals in efficacy, safety and quality testing in the production of biologicals and pharmaceuticals for animals.
Intervet would like to see the scope interpreted as broadly as possible. It can cover, for example, residue testing, new toxicological methods, challenging test replacements, epidemiological studies focusing on the correlation of field data and protection of animals by vaccination, new epitope identification, genomics, proteomics, alternatives to production methods using animal by-products or animals.
The applications will initially be screened by Intervet at the country level by a selection team consisting of an Intervet representative, a clinician and a public research centre representative. The judgment laid down in an expert report will form the basis for the final selection of candidates from the different regions.
The award is named after Dieter Lütticken. Dieter Lütticken, committed to research in microbiology and virology, contributed to Intervet research and development for more than a quarter of a century. With his ambition, creativity and broad knowledge in basic and applied science he guided and shaped Intervet's R&D for many years. He established what became tradition – Intervet's sound support and close collaboration with basic research. Dieter Lütticken retired in June 2003 from his position as Vice President and Intervet's Head of R&D.
Intervet welcomes submissions from all life-science research institutions. Commercial organizations are excluded. This year’s deadline is September 30, 2005.
Note for the editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,024 million in 2004, is dedicated to research and development, production and marketing of innovative animal health products and feed additives. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products, other pharmaceutical specialties and feed additives. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people.
Internet: www.intervet.com
Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Consolidated revenues for 2004 totaled EUR 12.9 billion. The Company currently employs some 61,000 people in more than 80 countries. The financial results for the second quarter will be published on July 20, 2005. Internet: www.akzonobel.com
Not for publication – For more information please contact
Sabine Schueller
Communications & Public Affairs
Intervet International bv
Tel: +31 (0)485 587085
Fax:+31 (0)485 585392
communications@intervet.com
